14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $21.75 $29.07 Wednesday, 24th Apr 2024 ARWR stock ended at $23.29. This is 2.06% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 3.71% from a day low at $22.89 to a day high of $23.74.
90 days $21.75 $36.72
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
Oct 24, 2023 $24.92 $25.42 $24.79 $25.03 566 357
Oct 23, 2023 $25.20 $25.38 $24.66 $24.69 665 911
Oct 20, 2023 $25.48 $26.42 $25.36 $25.44 966 370
Oct 19, 2023 $26.03 $26.17 $25.24 $25.35 1 033 371
Oct 18, 2023 $26.82 $27.14 $25.78 $25.99 1 017 202
Oct 17, 2023 $25.93 $27.68 $25.88 $27.02 1 205 600
Oct 16, 2023 $26.76 $26.84 $25.99 $26.51 851 402
Oct 13, 2023 $26.00 $26.72 $25.89 $26.60 944 838
Oct 12, 2023 $26.54 $26.60 $25.85 $25.88 1 288 342
Oct 11, 2023 $25.44 $26.49 $25.34 $26.46 1 157 247
Oct 10, 2023 $24.87 $25.66 $24.53 $25.63 910 146
Oct 09, 2023 $24.97 $25.10 $24.19 $24.97 591 315
Oct 06, 2023 $25.25 $25.80 $25.01 $25.19 621 002
Oct 05, 2023 $23.48 $25.57 $23.44 $25.55 1 644 469
Oct 04, 2023 $25.26 $25.58 $23.63 $23.77 1 281 440
Oct 03, 2023 $26.07 $26.12 $24.65 $25.16 1 087 144
Oct 02, 2023 $26.52 $26.69 $25.94 $26.25 1 343 870
Sep 29, 2023 $27.13 $27.41 $26.35 $26.87 806 416
Sep 28, 2023 $26.33 $27.31 $26.04 $26.93 759 799
Sep 27, 2023 $26.37 $26.66 $26.08 $26.39 643 000
Sep 26, 2023 $26.75 $27.32 $26.19 $26.20 1 046 058
Sep 25, 2023 $26.98 $27.12 $26.37 $26.67 640 540
Sep 22, 2023 $27.28 $27.64 $27.04 $27.24 574 631
Sep 20, 2023 $27.25 $27.49 $26.89 $27.01 820 225
Sep 19, 2023 $28.02 $27.94 $27.16 $27.23 612 294
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT